Written by: Dr. Ananya Sharma, MBBS, MD (Internal Medicine)
Medically Reviewed by: Dr. Rajesh Kumar, DM (Medical Oncology)
Last Updated: February 2026
Key Facts at a Glance
- Sample Required: Blood or saliva (for genetic testing)
- Fasting Rules: No fasting required
- Turnaround Time (TAT): 2–3 weeks for genomic profiling
- Base Cost: [Insert Current 2026 Price]
In a landmark clinical trial at University College London Hospital (UCLH), a 43-year-old father with glioblastoma—one of the most aggressive brain cancers—achieved complete remission after receiving the immunotherapy drug ipilimumab before standard treatment. This case, reported in early 2026, offers new hope for a disease with a historically poor prognosis.
Understanding Glioblastoma
Glioblastoma (GBM) is a grade IV astrocytoma characterized by rapid proliferation and infiltration into surrounding brain tissue. Despite aggressive multimodal therapy—surgery, radiation, and temozolomide—the median overall survival remains approximately 15 months, with a 5-year survival rate of only 5%. The tumor's heterogeneity and immunosuppressive microenvironment contribute to treatment resistance.
Immunotherapy Before Standard Treatment
The investigational protocol involved administering a single dose of ipilimumab, a CTLA-4 checkpoint inhibitor, before surgical resection and chemoradiation. This timing aims to prime the immune system while it is still intact, potentially enhancing antitumor immunity. The trial, led by UCLH, is now being expanded to 16 additional patients following the remarkable response observed in the index case.
Case Report: Ben Trotman
Ben Trotman, diagnosed in October 2022, received one dose of ipilimumab prior to surgery and standard adjuvant therapy. Post-treatment imaging revealed complete resolution of the tumor, and he has remained disease-free for over two years and eight months. This outcome is exceptionally rare, and while not generalizable, it underscores the potential of neoadjuvant immunotherapy in GBM.
"I know how rare this outcome is, and I just hope my story gives others a reason to hope." — Ben Trotman
Standard vs. Investigational Approach
| Aspect | Standard Care | Investigational Protocol |
|---|---|---|
| Timing of Immunotherapy | Usually after surgery/radiation | Before surgery (neoadjuvant) |
| Immune Status | Potentially compromised by prior treatment | Preserved, allowing robust immune response |
| Evidence Base | Established, but limited efficacy | Early-phase trial, promising but not yet standard |
The Role of Genomic Testing in Glioblastoma
Molecular profiling is increasingly critical in GBM management. Next-Generation Sequencing (NGS) and Whole Exome Sequencing (WES) can identify actionable mutations (e.g., IDH1, MGMT promoter methylation) that guide prognosis and treatment selection. DNA Labs India offers comprehensive genomic panels using NGS technology, aiding oncologists in personalizing therapy.
For patients seeking genetic insights, DNA Labs India provides ISO 9001 certified testing services with rapid turnaround and expert interpretation.
Why This Matters
- Glioblastoma remains a formidable challenge; any advance is significant.
- Immunotherapy sequencing may improve outcomes by leveraging the immune system's full capacity.
- Genomic testing can identify patients most likely to benefit from immunotherapy.
Future Directions
The UCLH trial expansion will provide more data on efficacy and safety. If positive, neoadjuvant ipilimumab could become a new standard of care. Meanwhile, ongoing research into combination immunotherapies and biomarkers will refine patient selection.